Type Whole antibody ATC code none CAS Number 1044758-60-2 | Legal status Investigational | |
Target β7 subunit of α4β7 and αEβ7 integrin heterodimers | ||
Etrolizumab (rhuMAb Beta7) is a biopharmaceutical drug candidate being developed for the treatment of ulcerative colitis and Crohn's disease. It is a humanized monoclonal antibody against the β7 subunit of integrins α4β7 and αEβ7. Etrolizumab was developed by Genentech by engineering the FIB504 antibody to include human IgGl-heavy chain and κ-light chain frameworks; it is manufactured in CHO cells.
As of 2016 it was in phase III studies for induction and maintenance therapy in people with ulcerative colitis and Crohn's.
References
Etrolizumab Wikipedia(Text) CC BY-SA